Advances in New Technology Add-On Payments for Innovative Medicine in China’s DRG/DIP Framework
In July, China’s National Healthcare Security Administration introduced the CHS-DRG Grouping Plan (Version 2.0), expanding the number of
Capitalizing on Specialized Medical Services in China: Opportunities for Innovative Life Sciences Manufacturers
To take advantage of these opportunities, manufacturers must focus on three key success factors.
Three Key Trends Shaping Pricing for Innovative Non-VBP Medical Devices in China
Understanding and strategically applying these trends is crucial for optimizing pricing strategies and enhancing market adoption of innovative medical technologies in China.
5 Trillion-Yuan Equipment Renewal and China's National Quota System for Large Medical Equipment
In China, large medical equipment is managed through a planned allocation and permit system. Medical institutions must follow specific plans, meet clinical and functional requirements, and have the necessary technical infrastructure and qualified staff.
NHSA Quietly Releases Implementation Guides for Establishing Medical Service Pricing Items
Executive Summary
In China, both public and private not-for-profit hospitals are required to adhere to the Medical Service Pricing Catalogs
China Aims to Establish a High-Quality All-Inclusive Commercial Health Insurance System in Five Years
Executive Summary
City Commercial Health Insurance ("Huiminbao") has been rapidly advancing, focusing on protecting the entire population against
Shanghai Pilots: Leading Value-Based and Risk-Sharing Reimbursement for Medical Consumables in China
Shanghai utilizes value-based pricing negotiations and performance-linked payments for medical consumable reimbursements, providing insights into the future direction of high-value medical consumable reimbursement under China's basic medical insurance.
China's Commercial Health Insurance Formulary Development: Current State and Future Directions
Executive Summary
The commercial health insurance sector in China presents substantial opportunities for growth, with the development of commercial insurance
Accessing Innovative Orphan Therapies in China: Local Advancements
These local initiatives have developed unique early access programs and multi-level funding models for orphan therapies, addressing the core issue of covering high-cost rare disease drugs not included in the national catalog.
